Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Aug;52(2):241–244. doi: 10.1038/bjc.1985.183

The effects of the administration of tamoxifen, ethynyloestradiol, and prednisolone on the activities of certain enzymes of carbohydrate metabolism in primary human breast carcinomas in vivo.

N Deshpande, I Mitchell, M Maltinti, A Boi, L Di Martino
PMCID: PMC1977094  PMID: 3161533

Abstract

Postmenopausal patients with primary breast cancer were treated with tamoxifen, ethynyloestradiol or prednisolone for up to 12 days before mastectomy and the effects of pretreatments with these drugs on the activities of phosphofructokinase (PFK), 6-phosphogluconate dehydrogenase (6PGDH) and alpha-glycerolphosphate dehydrogenase (alpha-GPDH) in the carcinomas were compared with age, stage and menopausal status matched untreated controls. The administration of tamoxifen or prednisolone resulted in a significant increase in the activity of alpha-GPDH and the alpha-GPDH/6PGDH ratio, whereas ethynyl-oestradiol treatment produced a significant decrease in the activity of the enzyme and the ratio. When tamoxifen and ethynyl-oestradiol were administered together, it was found that tamoxifen failed to reverse the oestrogen-induced reduction in the activity of alpha-GPDH. Since increased activity of the enzyme or a higher alpha-GPDH/6PGDH ratio are associated with a lower risk of recurrence (Deshpande et al., 1981), it is postulated that the beneficial effects of tamoxifen or prednisolone in terms of prolongation of the relapse free interval might be mediated via alterations in the activity of alpha-GPDH in micrometastases. The activities of PFK and 6PGDH remained unaffected by these treatments.

Full text

PDF
241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baum M., Brinkley D. M., Dossett J. A., McPherson K., Patterson J. S., Rubens R. D., Smiddy F. G., Stoll B. A., Wilson A., Lea J. C. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983 Aug 20;2(8347):450–450. doi: 10.1016/s0140-6736(83)90406-3. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976 Feb 19;294(8):405–410. doi: 10.1056/NEJM197602192940801. [DOI] [PubMed] [Google Scholar]
  4. Deshpande N., Mitchell I., Millis R. Tumour enzymes and prognosis in human breast cancer. Eur J Cancer. 1981 Apr;17(4):443–448. doi: 10.1016/0014-2964(81)90253-x. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Carbone P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Katrych D. L. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975 Jan 16;292(3):117–122. doi: 10.1056/NEJM197501162920301. [DOI] [PubMed] [Google Scholar]
  6. Katzenellenbogen B. S., Norman M. J., Eckert R. L., Peltz S. W., Mangel W. F. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res. 1984 Jan;44(1):112–119. [PubMed] [Google Scholar]
  7. Lam H. Y. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 1984 Jan 13;118(1):27–32. doi: 10.1016/0006-291x(84)91062-3. [DOI] [PubMed] [Google Scholar]
  8. Meakin J. W., Allt W. E., Beale F. A., Brown T. C., Bush R. S., Clark R. M., Fitzpatrick P. J., Hawkins N. V., Jenkin R. D., Pringle J. F. Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J. 1979 May 19;120(10):1221–1229. [PMC free article] [PubMed] [Google Scholar]
  9. Mitchell I., Deshpande N. Drug effects on certain enzymes of carbohydrate metabolism in MCF-7 cells in culture. Clin Oncol. 1984 Sep;10(3):253–260. [PubMed] [Google Scholar]
  10. SHONK C. E., BOXER G. E. ENZYME PATTERNS IN HUMAN TISSUES. I. METHODS FOR THE DETERMINATION OF GLYCOLYTIC ENZYMES. Cancer Res. 1964 May;24:709–721. [PubMed] [Google Scholar]
  11. Sutherland R. L., Hall R. E., Taylor I. W. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 1983 Sep;43(9):3998–4006. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES